CompletedPhase 3NCT01029262
A Study of Lenalidomide Versus Placebo in Subjects With Transfusion Dependent Anemia in Lower Risk Myelodysplastic Syndrome (MDS) Without Del 5q
Studying Myelodysplastic neoplasm with low blasts
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Celgene
- Principal Investigator
- Albert Hoenekopp, MDCelgene Corporation
- Intervention
- Lenalidomide(drug)
- Enrollment
- 239 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2010 – 2018
Study locations (30)
- University of California at Los Angeles, Los Angeles, California, United States
- Southern Illinois Hematology Oncology, Centralia, Illinois, United States
- Dartmouth Hitchcock Medical Center Norris Cotton Cancer Center, Lebanon, New Hampshire, United States
- Hackensack University Medical Center, Hackensack, New Jersey, United States
- Columbia University Medical Center, New York, New York, United States
- University of Texas MD Anderson Cancer Center, Houston, Texas, United States
- Medical College of Wisconsin, Milwaukee, Wisconsin, United States
- Wollongong Hospital, Wollongong, New South Wales, Australia
- Royal Adelaide Hospital Institute of Medical and Veterinary Science, Adelaide, South Australia, Australia
- Princess Alexandra Hospital, Woolloongabba, Australia
- Medizinische Universitat Innsbruck, Innsbruck, Austria
- Krankenhaus der Elisabethinen Linz, I Interne Abteilung, Linz, Austria
- Universitatsklinik fur Innere Medizin Salzburg, Salzburg, Austria
- Wiener Gebietskrankenkasse-Hanusch-Krankenhaus, Vienna, Austria
- Klinikum Wels-Grieskirchen GmbH, Weis, Austria
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT01029262 on ClinicalTrials.govOther trials for Myelodysplastic neoplasm with low blasts
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT07328191Quality of Life-Guided Transfusion in Refractory MDS or AMLCentre Hospitalier Universitaire de Nice
- RECRUITINGNCT07019155Study of Individuals and Families With Aberrations in DDX41 or Similar Cancer Predisposition VariantsNational Cancer Institute (NCI)
- RECRUITINGPHASE2NCT06918834Efficacy of Immediate Allogeneic Hematopoietic Stem Cell Transplantation Versus Bridging Therapy Followed by Transplantation in Higher-Risk Myelodysplastic Syndrome PatientsInstitute of Hematology & Blood Diseases Hospital, China
- ACTIVE NOT RECRUITINGNCT06144515Collection of Samples of Bone Marrow Aspiration From Patients With Myelodysplastic SyndromeMinovia Therapeutics Ltd.
- RECRUITINGPHASE2NCT05924100Efficacy and Safety of Luspatercept for the Treatment of Anemia Due to MDS With del5q, Refractory/Resistant/Intolerant to Prior Treatments, RBC-TDAssociazione Qol-one
- RECRUITINGPHASE1NCT05473910A Study of TSC-100 and TSC-101 in AML, ALL and MDS in Patients Undergoing Allogeneic Peripheral Blood Stem TransplantationTScan Therapeutics, Inc.
- RECRUITINGNCT02269592Study of MGUS, Smoldering Myeloma, Early MDS and CLL to Assess Molecular Events of Progression and Clinical OutcomeDana-Farber Cancer Institute
See all trials for Myelodysplastic neoplasm with low blasts →